Bg pattern

LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG

Lidocaine, Epinephrine

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist.

  • Keep this leaflet, as you may need to read it again.
  • If you need advice or more information, consult your pharmacist.
  • If you experience side effects, consult your doctor or pharmacist, even if it is a side effect not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG and what is it used for
  2. What you need to know before you start using Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG
  3. How to use Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG
  4. Possible side effects
  5. Storage of Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG
  6. Package Contents and Additional Information

1. What is Lidocaine/Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG and what is it used for

Lidocaine / Epinephrine Dermogen is a solution for injection. It is presented in a cartridge, in a single-unit package, a package of 50 cartridges, and a package of 100 cartridges.

Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG is indicated for local dental anesthesia, by infiltration or trunk block.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using Lidocaine/Epinephrine Dermogen 20 mg/ml + 0.125 mg/ml Solution for Injection EFG

Do not use Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG:

  • If you are allergic to the active substances, local anesthetics of the amide type, or to any of the other components of this medicine listed in section 6.
  • If you have closed-angle glaucoma (increased intraocular pressure), paroxysmal tachycardia (rapid pulse), or absolute arrhythmia with high frequency (cardiac rhythm disorder).
  • Do not administer intravenously.

Warnings and Precautions

Take into account before starting the administration of Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG:

  • If you have any liver disorder. If the disorder is severe, special caution should be taken, as toxic concentrations of lidocaine may be reached.
  • If you have kidney disease, as the anesthetic or its derivatives may accumulate.
  • If you are being treated with monoamine oxidase inhibitor drugs, tricyclic antidepressants, or phenothiazines, and if you are undergoing treatment with non-cardioselective beta-blockers.
  • If you have cardiovascular dysfunction, as the depressive cardiac effects may be increased.
  • If you are sensitive to drugs, especially anesthetics or other chemically related components.
  • It may contribute to the development of malignant hyperthermia in case supplementary anesthesia is required.
  • Oxygen, equipment, and resuscitation medications should be readily available.
  • Avoid injection into an inflamed or infected area.

Consult if any of the above circumstances have occurred to the patient at any time.

Other Medicines and Lidocaine/ Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG:

Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medicine, even those obtained without a prescription. Some medicines may influence the action of others.

The following medicines are not recommended for administration:

  • Tricyclic antidepressants or monoamine oxidase inhibitors (MAO): may increase the vasoconstrictor effect of epinephrine.
  • Phenothiazine and butyrophenones: may reduce or reverse the vasoconstrictor effect of epinephrine.
  • Non-cardioselective beta-blocker drugs (e.g., propranolol).
  • Central nervous system depressants: may result in additive depressive effects.
  • Disinfectant solutions containing heavy metal ions: lidocaine releases the ions from these solutions, which may cause significant local irritation and swelling.
  • Beta-adrenergic blockers: may slow down the metabolism of lidocaine due to decreased hepatic blood flow, which may increase the risk of lidocaine toxicity.
  • Cimetidine: may inhibit the hepatic metabolism of lidocaine, leading to an increased risk of lidocaine toxicity.
  • Neuromuscular blockers: the anesthetic may prolong or potentiate the action of these types of drugs.

Intramuscular injection of lidocaine may produce an increase in phosphokinase levels.

Using Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG with Food:

After administration of Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG, do not ingest food until sensitivity has been restored.

Pregnancy and Breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Pregnancy:Consult your doctor or pharmacist before using a medicine. Caution should be exercised when prescribing to pregnant women.

No clinical data on lidocaine in pregnant women are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development, birth, or postnatal development.

Breastfeeding:Consult your doctor or pharmacist before using a medicine. Lidocaine is excreted in small amounts in breast milk. Although the potential consequences in the infant are unknown, the potential for adverse effects appears to be low.

Driving and Using Machines

Although no effects on the ability to drive vehicles are expected, the dentist will decide when you are able to drive and operate machinery.

Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG contains Sodium Metabisulfite (E-223)

This medicine contains sodium metabisulfite (E-223) as an excipient. It can rarely cause severe allergic reactions and bronchospasm (sudden feeling of suffocation).

Athletes should be aware that lidocaine may produce a positive result in doping tests.

3. How to use Lidocaine/Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG

Your dentist will determine the dose and method of administration of Lidocaine / Epinephrine Dermogen.

The recommended dose is:

  • For infiltrations or terminal anesthesia, it is generally sufficient to administer 1 ml of Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG.
  • For trunk anesthesia, the dose will be 1.5 to 2 ml.
  • The maximum dose in 24 hours is 500 mg of lidocaine, and it should not exceed 7 mg/kg of body weight in adults.

Do not take food until sensitivity has been restored.

If you use more Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG than you should

Respiratory, circulatory, and convulsive complications may occur. If they occur, administration will be interrupted, and adequate treatment will be initiated.

In case of overdose or accidental ingestion, consult the Toxicology Information Service (Tel. 91 562 04 20), indicating the product and the amount received.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible Side Effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common(>1/100, <1/10):excitement, agitation, dizziness, tinnitus (ringing in the ears), blurred vision, nausea, vomiting, tremors, and convulsions. Numbness of the tongue and perioral region. After excitement, depression with drowsiness, respiratory alterations that can lead to respiratory arrest and coma, even with cardiac alterations (myocardial depression), low blood pressure (hypotension), decreased heart rate (bradycardia), arrhythmia, and cardiac arrest.

Very Rare(<1/10,000):Allergic reactions (urticaria, anaphylactoid reaction), blood disorders (methemoglobinemia).

Other Adverse Reactions:Epinephrine may cause rapid heart rate (tachycardia), cardiac rhythm disorders, increased blood pressure, although it is extremely rare.

If you notice any of these reactions or any other reaction not described in this leaflet, consult your doctor or pharmacist.

Reporting of Side Effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Lidocaine/Epinephrine Dermogen 20 mg/ml + 0.125 mg/ml Solution for Injection EFG

Keep Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG out of the reach and sight of children.

Do not store above 30°C. Keep the blister in the outer packaging to protect it from light. Do not freeze.

Do not use this medicine after the expiration date stated on the packaging after Exp. The expiration date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and medicines you no longer need in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG

  • The active substances are lidocaine and epinephrine.
  • The other excipients are: Sodium Metabisulfite (E-223), sodium chloride, water for injection.

Appearance of the Product and Package Contents

Lidocaine / Epinephrine Dermogen 20 mg/ml + 0.0125 mg/ml Solution for Injection EFG is presented as a solution for injection in glass cartridges. Single-unit package containing one cartridge and a leaflet. Package containing 50 cartridges of 1.8 ml and a leaflet. Clinical package containing 100 cartridges in a blister support and a leaflet.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

FARMALIDER, S.A.

C/La Granja, 1

28108-Alcobendas, Madrid

Spain

Manufacturer

PIERREL, S.P.A.

Via Nazzionale Appia (Capua, Caserta) I-81043

Italy

Date of the Last Revision of this Leaflet:04/2017.

Other Sources of Information

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products.

……………………………………………………………………………………………………

This information is intended only for healthcare professionals

Method of Administration

By injection into the oral mucosa.

FOR USE ONLY IN DENTAL ANESTHESIA.

To avoid intravascular injection, aspiration control should always be performed in at least two planes (rotation of the needle by 180°), although a negative aspiration result does not rule out involuntary and unnoticed intravascular injection.

The injection speed should not exceed 0.5 ml in 15 seconds, i.e., 1 cartridge/minute.

Major systemic reactions, such as those resulting from accidental intravascular injection, can be avoided in most cases by a technical injection (after aspiration, slow injection of 0.1-0.2 ml and slow application of the rest), not before 20-30 seconds have passed.

Opened cartridges should not be used in other patients. Residues should be discarded.

Precautions for Use.

Each time a local anesthetic is used, the following medications/therapies should be available:

  • - Anticonvulsant medications (benzodiazepines or barbiturates), muscle relaxants, atropine, and vasopressors or epinephrine for severe allergic or anaphylactic reactions.
  • - Resuscitation equipment (in particular, an oxygen source) capable of artificial ventilation if necessary.
  • - Careful and constant monitoring of cardiovascular and respiratory vital signs (adequate ventilation) and the patient's state of consciousness should be controlled after each local anesthetic injection. Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous system toxicity.

Therapy in Cases of Overdose

Basic General Measures:

Hypertension: Elevation of the upper body, if necessary, nifedipine will be administered sublingually.

Convulsions: The patient will be protected from simultaneous damage, if necessary, benzodiazepines (e.g., diazepam i.v.) will be administered.

Hypotension: Horizontal position, if necessary, intravascular infusion of a complete electrolytic solution, vasopressor (e.g., ethylephrine i.v.).

Bradycardia: Atropine i.v.

Anaphylactic shock: Contact an emergency doctor, meanwhile, shock position, generous infusion of a complete electrolytic solution, if necessary, adrenaline i.v., cortisone i.v.

Cardiovascular arrest: Immediate cardiopulmonary resuscitation, contact the emergency doctor.

Online doctors for LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION

Discuss questions about LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (5)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
Camera Book a video appointment
€130

Frequently Asked Questions

Is a prescription required for LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION?
LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION?
The active ingredient in LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION is lidocaine, combinations. This information helps identify medicines with the same composition but different brand names.
Who manufactures LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION?
LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION is manufactured by Farmalider S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to LIDOCAINE/EPINEPHRINE DERMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION?
Other medicines with the same active substance (lidocaine, combinations) include LIDOCAINE / EPINEPHRINE AGUETTANT 20 mg/mL + 0.005 mg/mL INJECTABLE SOLUTION, LIDOCAINE/ADRENALINE AGUETTANT 10 mg/mL + 0.005 mg/mL INJECTABLE SOLUTION, LIDOCAINE/ADRENALINE NORMOGEN 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media